Gujarat Inject (Kerala)
Gujarat Inject (Kerala) (GUJINJEC) share price was ₹10.66 at the 27 Oct 2026 close; market capitalisation ₹156 Cr; P/E (TTM) 53.30; sector Healthcare. The share price rose 407.6% over the year to 27 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue was ₹12.45 Cr, against ₹2.42 Cr a year earlier and net profit was ₹1.25 Cr, against ₹0.07 Cr a year earlier (compared with Jun 2025). Promoters held 0.00% of Gujarat Inject (Kerala) in Jun 2026, unchanged from Mar 2026. Its Tapetide Score is 53/100 (Average) as of 28 Oct 2026.
Key Fundamentals
MicrocapPharmaceuticalsHealthcarePrice-based figures as of 27 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| ₹1,767.20 | 35.06 | 4,24,010 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,655.00 | 87.63 | 2,56,310 Cr | 15.29 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,604.50 | 72.28 | 1,75,140 Cr | 9.53 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,187.30 | 108.07 | 1,18,182 Cr | 22.30 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,181.00 | 26.28 | 1,17,805 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,338.40 | 34.66 | 1,11,714 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,362.50 | 32.64 | 1,10,071 Cr | 3.11 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Gujarat Inject (Kerala) (this company) | — | 53.30 | 156 Cr | 13.16 | 0.00% | 15.34% | 21.17% | 47 Cr | 3 Cr |
| Median 8 companies | ₹1,767.20 | 44.18 | 1,17,994 Cr | 7.30 | 0.47% | 14.56% | 18.45% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 95/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Debtor days have improved from 130 to 63.8 days.
Weaknesses
2- Stock is trading at 11.3 times its book value
- Company has a low return on equity of 12.1% over last 3 years.
Technical Indicators
Oscillators
Bearish
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 13.57% · Jun 2026
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.15 | 0 | 0.22 | 5.42 | 3.05 | 8.61 | 3.15 | 4.24 | 2.42 | 1.58 | 1.63 | 30.7 | 12.45 |
| Expenses | 0.11 | 0 | 0.25 | 5.37 | 2.88 | 8.07 | 2.87 | 4.15 | 2.32 | 1.55 | 1.72 | 28.43 | 10.76 |
| Operating Profit | 0.04 | 0 | -0.03 | 0.05 | 0.17 | 0.54 | 0.28 | 0.09 | 0.1 | 0.03 | -0.09 | 2.27 | 1.69 |
| OPM % | 26.67% | — | -13.64% | 0.92% | 5.57% | 6.27% | 8.89% | 2.12% | 4.13% | 1.9% | -5.52% | 7.39% | 13.57% |
| Other Income | 0 | 0.02 | 0.04 | 0 | 0 | 0.17 | 0 | 0.01 | 0 | 0.06 | 0.14 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0.04 | 0.02 | 0.01 | 0.05 | 0.17 | 0.71 | 0.28 | 0.1 | 0.1 | 0.09 | 0.05 | 2.27 | 1.69 |
| Tax % | 25% | 0% | 0% | 20% | 23.53% | 14.08% | 25% | 30% | 20% | 22.22% | 20% | 27.75% | 26.04% |
| Net Profit | 0.03 | 0.01 | 0 | 0.04 | 0.12 | 0.61 | 0.21 | 0.07 | 0.07 | 0.07 | 0.04 | 1.64 | 1.25 |
| EPS (₹) | 0.01 | 0 | 0 | 0 | 0.01 | 0.04 | 0.01 | 0 | 0 | 0 | 0 | 0.11 | 0.09 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0.02 | 1.57 | 0 | 0 | 0 | 0.01 | 0.02 | 0.17 | 5.79 | 19.05 | 36.32 | 46.36 |
| Expenses | 0 | 0.02 | 1.56 | 0.07 | 0.03 | 0.01 | 0.13 | 0.07 | 0.54 | 5.74 | 17.98 | 34.02 | 42.46 |
| Operating Profit | 0 | 0 | 0.01 | -0.07 | -0.03 | -0.01 | -0.12 | -0.05 | -0.37 | 0.05 | 1.07 | 2.3 | 3.9 |
| OPM % | — | 0% | 0.64% | — | — | — | -1200% | -250% | -217.65% | 0.86% | 5.62% | 6.33% | 8.41% |
| Other Income | 0 | 2.3 | 0 | 0.05 | 0.02 | 0.01 | 0.01 | 0.05 | 0.43 | 0.06 | 0.18 | 0.2 | 0.2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | 2.3 | 0.01 | -0.02 | -0.01 | 0 | -0.11 | 0 | 0.06 | 0.11 | 1.25 | 2.5 | 4.1 |
| Tax % | — | 0% | 0% | 0% | 0% | — | 0% | — | 16.67% | 18.18% | 19.2% | 27.6% | — |
| Net Profit | 0 | 2.3 | 0.01 | -0.02 | -0.01 | 0 | -0.11 | 0 | 0.04 | 0.08 | 1.02 | 1.81 | 3 |
| EPS (₹) | 0 | 0.47 | 0 | 0 | 0 | 0 | -0.02 | 0 | 0.01 | 0.01 | 0.07 | 0.12 | 0.2 |
| Div. Payout % | — | 0% | 0% | 0% | 0% | — | 0% | — | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 11.29 | 14.63 | 14.63 |
| Reserves | -7.95 | -5.64 | -5.64 | -5.66 | -5.66 | -5.66 | -5.77 | -5.76 | -5.72 | -2.75 | -4.62 | -2.81 |
| Borrowings | 2.86 | 0.56 | 0.57 | 0.59 | 0.59 | 0.59 | 0.69 | 0.73 | 0.61 | 0 | 0 | 0 |
| Other Liabilities | 0.38 | 0.36 | 0.2 | 0.21 | 0.2 | 0.2 | 0.22 | 0.22 | 0.53 | 0.15 | 1.94 | 24.85 |
| Total Liabilities | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.3 | 8.69 | 11.95 | 36.67 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20.76 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.3 | 8.69 | 11.95 | 15.91 |
| Total Assets | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.3 | 8.69 | 11.95 | 36.67 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 0 | 0 | -0.01 | 0 | 0 | -0.11 | 0 | 0.05 | -6.03 | -3.52 | 21.22 |
| Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.18 | -20.57 |
| Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 | 8.88 | 0.45 | 0 |
| Net Cash Flow | 0 | 0 | 0 | -0.01 | 0 | 0 | 0 | 0 | 0.05 | 2.86 | -2.89 | 0.65 |
| Free Cash Flow | 0 | 0 | 0 | -0.01 | 0 | 0 | -0.11 | 0 | 0.05 | -6.03 | -3.52 | 0.46 |
| CFO/OP | — | — | 0 | 14 | 0 | 0 | 92 | 0 | -16 | -12,020 | -307 | 953 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | 0 | 0 | — | — | — | 0 | 0 | 0 | 188 | 138 | 63.81 |
| Inventory Days | — | — | 0 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Conversion Cycle | — | 0 | 0 | — | — | — | 0 | 0 | 0 | 188 | 138 | 63.81 |
| Working Capital Days | — | -8,395 | -107 | — | — | — | -17,520 | -9,490 | -1,546 | 355 | 138 | -140 |
| ROCE % | — | — | — | — | — | — | — | — | — | 2.65% | 13.48% | 22.9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Gujarat Inject (Kerala) insights
57 extracted metrics + investor summaries across FY04–FY27.
Documents
Frequently Asked Questions about Gujarat Inject (Kerala)
What does Gujarat Inject (Kerala) Ltd do?
Where is Gujarat Inject (Kerala) Ltd (GUJINJEC) listed?
Which sector does Gujarat Inject (Kerala) Ltd belong to?
What is the market capitalisation of Gujarat Inject (Kerala) Ltd?
What is the PE ratio of Gujarat Inject (Kerala) Ltd?
What is the 52-week high and low of Gujarat Inject (Kerala) Ltd?
What is the Return on Equity (ROE) of Gujarat Inject (Kerala) Ltd?
Company Information
Gujarat Inject (Kerala) Ltd has discontinued its legacy pharmaceutical manufacturing operations and currently follows a trading -led business model transitioning towards renewable energy. Its disclosed activities include supplying 600–620Wp solar-PV modules, investing in a 5MW solar project and evaluating thermal-energy-storage opportunities.[1] [2] [3]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524238.md for Gujarat Inject (Kerala) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.